fig3
![Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer progression and opportunities for drug targeting](https://image.oaes.cc/6add4925-e9e0-4707-b75e-36d8c6447f6e/2315.fig.3.png)
Figure 3. Structure of ICT2588 and MT-MMP targeting concept. Peptide conjugation renders the drug (azademethylcolchicine) pharmacologically inactive. Following initial MT-MMP recognition and cleavage, the remaining amino acids are metabolised to release the toxic drug selectively in the tumor microenvironment. MT-MMP: membrane-type matrix metalloproteinases